Virtus ETF Advisers LLC Relmada Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $915 - $1,851	50 Added 0.82%	6,118 $226,000
Q2 2022 Aug 12, 2022	SELL	$16.5 - $30.34 $40,392 - $74,272	-2,448 Reduced 28.75%	6,068 $115,000
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $8,343 - $13,468	-499 Reduced 5.54%	8,516 $230,000
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $39,142 - $62,007	2,312 Added 34.49%	9,015 $203,000
Q3 2021 Nov 15, 2021	SELL	$21.86 - $34.77 $7,716 - $12,273	-353 Reduced 5.0%	6,703 $176,000
Q2 2021 Aug 10, 2021	SELL	$29.55 - $39.15 $55,879 - $74,032	-1,891 Reduced 21.14%	7,056 $226,000
Q1 2021 May 17, 2021	BUY	$31.52 - $39.28 $5,169 - $6,441	164 Added 1.87%	8,947 $315,000
Q4 2020 Feb 12, 2021	BUY	$29.88 - $39.8 $66,303 - $88,316	2,219 Added 33.81%	8,783 $282,000
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $30,943 - $39,358	-899 Reduced 12.05%	6,564 $247,000
Q2 2020 Aug 05, 2020	BUY	$31.59 - $49.98 $235,756 - $373,000	7,463 New	7,463 $334,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.